Promising results from early-phase clinical trials in cancers such as epithelioid sarcoma and follicular lymphoma highlight the potential of EZH2 inhibitors in targeting CSC populations through epigenetic reprogramming (Italiano et al., 2018). Here, EZH2 is linked to cancer.